Actively Recruiting
Intra Arterial Therapies in Treatment of Primary Liver Diseases: an Observational Study
Led by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Updated on 2025-01-14
3300
Participants Needed
1
Research Sites
4 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to identify the best conditions for positive outcomes in men and women undergoing intra arterial therapy (IAT) for primary liver cancer, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Intra arterial therapies are radiological procedures that block the blood supply to liver tumors. The study is observational, combining both retrospective and prospective data collected at a single hospital to analyze clinic and radiological factors influencing treatment response. The study involves analyzing data from patients who have received or will receive intra arterial therapies such as trans-arterial embolization (TAE), transarterial chemoembolization (TACE), transarterial radioembolization (TARE), and drug-eluting beads chemoembolization (DEB-TACE). Retrospective data from patients treated since January 2009 will be reviewed, while prospective participants will be followed for 5 years with regular follow-up every three months. All therapies are performed within routine clinical care without additional experimental drugs. Participants will have their radiological images like CT scans and MRIs examined to assess tumor type, size, and response to treatment, as well as to monitor for possible complications. Researchers will measure outcomes including the size and type of liver injury, radiological response, and post-treatment complications over a period of up to 9 years. The study involves ongoing follow-up visits to track these outcomes and collect clinical information during the study period.
CONDITIONS
Brief Title
Intra Artherial Therapies in Treatment of Primary Liver Diseases: an Observational Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of hepatocellular carcinoma or intrahepatic cholangiocarcinoma
- Clinical indication to receive or have received trans-arterial embolization, transarterial chemoembolization, transarterial radioembolization, or drug-eluting beads chemoembolization
- Age over 18 years
- Ability to give informed consent
You will not qualify if you...
- Presence of shunt of gastrointestinal arteries that cannot be embolized
- Metastasis spread outside of the liver
- Liver failure
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 9 years
Participants who undergo routine intra arterial therapies as part of their clinical care are observed to assess the type and size of the liver injury, track radiological response to therapy, and identify post treatment complications.
Follow-up visits every 3 months
Trial Site Locations
Total: 1 location
1
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Italy, 40138
Actively Recruiting
Research Team
C
Cristina Mosconi, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here